The FDA’s new health products policy isn’t the end of the road for the industry

Written by Sam Felt and Sam BilekRead more A group of scientists have published a new paper saying that a controversial health products rule that the FDA released last year will be a disaster for the health industry.

The report was authored by the New England Journal of Medicine and is available here. 

According to the authors, the new rules will prevent manufacturers from selling more than one product, limit the size of the product packaging, and require labeling on most products, such as sunscreen. 

The FDA rule, dubbed the Dietary Guidelines for Americans (DGAs), is widely considered to be a disastrous piece of legislation. 

A recent Gallup poll found that a majority of Americans support the new guidelines, with just 34% of people saying they don’t support them. 

Critics of the new guidance have claimed it will be bad for the economy, and a number of major companies, including Nestle, have already announced they are leaving the U.S. In the new paper, the researchers said that the DGAs will only have a minor impact on the health of consumers, because they don’t regulate the food supply as a whole, but rather concentrate on products that are specific to the health products industry. 

“The DGAs are intended to target the health-care and other specialty markets, and to be consistent with the dietary guidelines for Americans,” they wrote.

“However, these DGAs may have little impact on a wide range of health-related products, including personal care products, cosmetics, pharmaceuticals, and dietary supplements.

We suggest that the public be skeptical of this claim, and that they be wary of the DGA and its accompanying guidance.”

The researchers, who included researchers from Harvard University and Yale University, said that if the DGas were enacted, “it would be unlikely that DGAs would have any meaningful effect on the food and beverage industry.” 

The researchers said they plan to release a report later this year showing how the FDA’s DGAs might impact health products.